


## Approval by Ethics Committee of LZU No. 1 Hospital

Approval No. :LDYYLL-2022-421	Date of review:30/09/2022	
Name of research plan: Umbilical Cord derived Mesenchymal Stem Cells ameliorate Experimental Autoimmune Hepatitis by inhibiting CD4+ T cell Migration and Th17 Differentiation		
Applicant/trial product/SFDA No. : The No. 1 Hospital of Lanzhou University	Type	Scientific research
Principal Investigator/organization: Xiaofeng Wei / The No. 1 Hospital of Lanzhou University		
Document (with version number)		
Research plan	<input checked="" type="checkbox"/> Have	<input type="checkbox"/> No
Waiver of Informed consent form	<input checked="" type="checkbox"/> Have	<input type="checkbox"/> No
Application for ethical review of animal experiments	<input checked="" type="checkbox"/> Have	<input type="checkbox"/> No
Results of Ethics Committee' s review:		
1. The Committee reviewed the technical plan and informed consent form for the participants, decisions for the program are as follows :		
<input checked="" type="checkbox"/> Approve		
<input type="checkbox"/> Approve after amendment		
<input type="checkbox"/> Disapprove		
<input type="checkbox"/> Termination or suspension		
2. Will the progress of the research reviewed by the ethics committee continually?		
<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
3. The frequency of review is once every <u>12 months</u> from the date of approval, the ethics committee has right to change the frequency of continued review based on actual progress.		
LZU No. 1 hospital Ethics Committee (Seal): 		
Date: 30/09/2022		